Alector, Inc.
NMS: ALECLive Quote
📈 ZcoreAI Score
Our AI model analyzes Alector, Inc.'s price action across multiple timeframes using regression channels and statistical scoring.
Get ALEC Z-Score →About Alector, Inc.
Healthcare
Biotechnology
Alector, Inc., a clinical stage biotechnology company, develops therapies to counteract the progression of neurodegeneration in the United States. Its pipeline includes Nivisnebart, an investigational human recombinant monoclonal antibody for treating prevalent neurodegenerative diseases; AL137, an anti-amyloid beta antibody paired in preclinical development for the potential treatment of Alzheimer's disease; and AL050, a GCase enzyme replacement therapy in preclinical development for the potential treatment of Parkinson's disease and Lewy body dementia in patients having GBA1 gene mutations. The company also develops its preclinical and research pipeline comprising AL064, a tau siRNA for Alzheimer's disease and other tauopathies; ADP062-ABC, an alpha-synuclein siRNA for Parkinson's disease; and ADP065-ABC, an NLRP3 siRNA for neurodegenerative conditions. It has a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of progranulin-elevating monoclonal antibodies, including Latozinemab and Nivisnebart. The company was founded in 2013 and is headquartered in South San Francisco, California.
📊 Fundamental Analysis
Alector, Inc. demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
The company recently reported -88.5% revenue growth, which is negative, indicating a recent decline in revenue.
Return on Equity (ROE) is -181.6%, which indicates that capital utilization is currently under pressure.
At a current price of $2.45, ALEC currently sits at the 62nd percentile of its 52-week range (Range: $0.90 - $3.40).
🏥 Financial Health
🔴
Profit Margin
Weak
🔴
Debt/Equity
Elevated
🔴
Revenue Growth
Weak
🔴
Return on Equity
Weak
✅
Beta (Risk)
Low Volatility
Key Financials
Market Cap
$270.39M
Trailing P/E
--
Forward P/E
-2.78
Beta (5Y)
0.58
52W High
$3.40
52W Low
$0.90
Avg Volume
866K
Day High
Day Low